齐拉西酮与利培酮治疗精神分裂症对照研究

目的评价齐拉西酮与利培酮治疗精神分裂症的临床疗效及安全性。方法将60例精神分裂症患者随机分为两组各30例，研究组口服齐拉西酮治疗，对照组口服利培酮治疗，观察6w。于治疗前及治疗第6w末采用阳性与阴性症状量表及副反应量表评定临床疗效和不良反应。结果治疗6w末研究组显效率为66．7％，对照组为70％。治疗6w末两组阳性与阴性症状量表各因子分及总分均较治疗前有极显著下降（P〈0．01）；同期两组比较差异均无显著性（P〉0．05）。两组不良反应程度均较轻微，发生率比较无显著性差异（P〉0．05）。结论齐拉西酮治疗精神分裂症的疗效与利培酮相当，不良反应轻微，安全性高，依从性好。

A control study on ziprasidone vs. risperidone in the treatment of schizophrenia

Objective To evaluate the clinical efficacy and safety of ziprasidone in the treatment of schizophrenia. Methods Sixty schizoprenies were randomly divided into research group（n=30） taking orally ziprasidone and control group（n= 30） doing risperidone for 6 weeks. Clinical efficacies were assessed with the Positive and Negative Syndrome Scale（PANSS） adverse reactions with the Treatment Emergent Symptom Scale（TESS） before treatment and at the end of the 6th week treatment. Results At the end of the 6th week, obviously effective rates were 66.7% in the research and 70% in the control group. Total and each factor score of the PANSS of both groups lowered more significantly at the end of the 6th week compared with pretreatment（P〈0.01）; there was no significant difference in synchronization infergroup comparisons（P〉0.05）. Adverse reactions of both groups were mild, their incidences had no differences（P〉 0.05）. Conclusion Ziprasidone has the same efficacy to risperidone, mild adverse reactions, higher safety and better compliance in the treatment of schizophrenia.